Povero, Davide
Tameda, Masahiko
Eguchi, Akiko
Ren, Wenhua
Kim, Jihoon
Myers, Robert
Goodman, Zachary D.
Harrison, Stephen A.
Sanyal, Arun J.
Bosch, Jaime
Ohno-Machado, Lucila
Feldstein, Ariel E.
Funding for this research was provided by:
Gilead Sciences
National Institute of Diabetes and Digestive and Kidney Diseases (DK113592)
National Institute on Alcohol Abuse and Alcoholism (AA024206)
Article History
Received: 9 September 2021
Accepted: 31 January 2022
First Online: 22 February 2022
Competing interests
: RPM is an employee and shareholder of Gilead Sciences, Inc. AJS’s institution received grants from Malinckrodt, Novartis, Conatus, Gilead, Intercept, Allergan, Novo Nordisk, Pfizer, Merck, Celgene, Axcella. He consults for Astra Zeneca, Merck, Pfizer, Gilead, Alnylam, Regeneron, Amgen, Roche, Lilly, Bristol Myers, Boehringer Ingelhiem, Axcella, Salix, Hemoshear, Novo Nordisk, Thera Pharmaceuticals, Malinckrodt, Terns, Inventiva, Siemens, Glympse, Covance, Prosciento, Zydus, Blade, and Lilly. He received royalties from Elsevier and Uptodate. He is President of Sanyal Bio and owns stock in Akarna, Genfit, Hemoshear, Galmed, Indalo, Durect, and Tiziana. The rest of the authors have no competing interests.